Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial

BACKGROUND: The radiochemotherapy regimen concomitantly employing temozolomide (TMZ) chemotherapy and radiotherapy (RT) 4 weeks after surgery, followed by 6 cycles of TMZ is a common treatment for glioblastoma (GBM). However, its median overall survival (OS) is only 14.6 months. This study was to ex...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chin Med J (Engl)
Main Authors: Mao, Ying, Yao, Yu, Zhang, Li-Wei, Lu, Yi-Cheng, Chen, Zhong-Ping, Zhang, Jian-Min, Qi, Song-Tao, You, Chao, Wang, Ren-Zhi, Yang, Shu-Yuan, Zhang, Xiang, Wang, Ji-Sheng, Chen, Ju-Xiang, Yang, Qun-Ying, Shen, Hong, Li, Zhi-Yong, Wang, Xiang, Ma, Wen-Bin, Yang, Xue-Jun, Zhen, Hai-Ning, Zhou, Liang-Fu
Formato: Artigo
Idioma:Inglês
Publicado em: Medknow Publications & Media Pvt Ltd 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4736883/
https://ncbi.nlm.nih.gov/pubmed/26481741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0366-6999.167313
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados